Compugen Ltd. logo
Compugen Ltd. CGEN
$ 1.83 -3.17%
report update icon

Quarterly report 2023-Q2
added 11-09-2026

Compugen Ltd. Revenue | CGEN

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Compugen Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
72.8 M 27.9 M 33.5 M 7.5 M 6 M 2 M - 17.8 M - 712 K 9.28 M 12.4 M 3.55 M 240 K - 1.12 M 250 K -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
72.8 M 240 K 13.9 M

Quarterly Revenue Compugen Ltd.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2009-Q4 2008-Q4
72.8 M 3.54 M 27.9 M 9.26 M 33.5 M - - - - - - 6 M - - 2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1.12 M 250 K -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
72.8 M 250 K 17.4 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Exicure Exicure
XCUR
500 K $ 0.96 -7.24 % $ 6.05 M usaUSA
Xencor Xencor
XNCR
126 M $ 33.48 -1.56 % $ 2.49 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
413 M $ 3.24 -5.55 % $ 710 M britainBritain
Daré Bioscience Daré Bioscience
DARE
1.03 M $ 0.41 -9.93 % $ 4.58 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
6.65 M $ 0.92 -9.07 % $ 109 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
1.4 B $ 91.28 -1.89 % $ 10.9 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
549 M $ 13.18 -2.04 % $ 11.3 B chinaChina
Aptorum Group Limited Aptorum Group Limited
APM
431 K - - $ 5.72 M chinaChina
iBio iBio
IBIO
100 K $ 0.83 3.01 % $ 86.4 M usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
146 M $ 0.02 -56.5 % $ 219 usaUSA
FSD Pharma FSD Pharma
HUGE
257 K - 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
300 K $ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
589 M - - $ 3.85 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
110 M $ 28.91 -8.89 % $ 1.39 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
117 M $ 13.01 0.74 % $ 1.16 B usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
3.2 K - - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
7.5 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
130 K - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
886 K - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
123 M - 1.93 % $ 17.4 M usaUSA
AlloVir AlloVir
ALVR
165 K - 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
1 B - - $ 5.18 B usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
58.7 B - - $ 96.9 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
5.34 B - 0.49 % $ 251 B cayman-islandsCayman-islands
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
31.4 M $ 0.23 -12.11 % $ 16.8 K usaUSA
Bio-Path Holdings Bio-Path Holdings
BPTH
37 K - - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
7.14 M - -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
129 M - -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
170 K - -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
1.1 M - -5.98 % $ 34.1 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
4.01 M - 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
6.36 M - -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
52 K - - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
403 M - - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
20.2 M - 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
813 K - 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
6.44 M - - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
53.7 M - 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
634 M - - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
6.39 M - - $ 528 M usaUSA
GlycoMimetics GlycoMimetics
GLYC
10.8 M - 9357.83 % $ 1.01 B usaUSA